Perspective Therapeutics updates corporate presentation; no material new information disclosed

Perspective Therapeutics, Inc.

Filing reports updated corporate presentation as Exhibit 99.1, but no specific new data or milestones are mentioned.
Presentation covers 212Pb radiopharmaceutical pipeline for neuroendocrine tumors and melanoma, and manufacturing supply chain.
No financial results, guidance changes, or regulatory events are presented in the filing or exhibit.
Updates appear to be routine corporate slides without substantive new disclosures for investors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.